Beijing Tide Pharmaceutical Co. Ltd. has divulged nanobody-drug conjugates comprising a nanobody targeting B7 homolog 3 (B7-H3, CD276) covalently bound to exatecan through a linker reported to be useful for the treatment of lung cancer.
Primelink Biotherapeutics (Shenzhen) Co. Ltd. has discovered molecular glue degraders acting as eukaryotic peptide chain release factor GTP-binding subunit ERF3A (GSPT1) degradation inducers reported to be useful for the treatment of cancer.
Beone Medicines (Beijing) Co. Ltd. has disclosed an antibody-drug conjugate comprising an antibody targeting fibroblast growth factor receptor 2 isoform 2 (FGFR2; FGFR2b) covalently linked to cytotoxic agent through a linker reported to be useful for the treatment of small-cell lung cancer (SCLC) and gastric cancer.
In a recent publication, researchers from The First Affiliated Hospital of Zhengzhou University (China) and collaborators investigated the association between phosphoglycerate kinase 1 (PGK1) expression in thyroid cancer tissues and clinicopathological features, postoperative recurrence and prognosis in papillary thyroid carcinoma (PTC). These observations may help advance clinical assessment and provide references for intervention strategies.
Simcere Zaiming Pharmaceutical Co. Ltd. has disclosed antibody-drug conjugates (ADC) comprising human monoclonal antibodies targeting zinc transporter ZIP6 (SLC39A6; LIV-1) covalently linked to cytotoxic drugs through a linker reported to be useful for the treatment of cancer.
Innovent Biologics (Suzhou) Co. Ltd. has described antibody-stimulating antibody conjugates (ISACs) comprising antibody targeting folate receptor α (FOLR1; FR-α) or tumor-associated calcium signal transducer 2 (TACSTD2; TROP2) covalently bound to toll-like receptor 7 (TLR7) and/or toll-like receptor 8 (TLR8) agonist through a linker reported to be useful for the treatment of cancer.
Sevenless Therapeutics Ltd. has patented son of sevenless homolog 1 (SOS1) inhibitors reported to be useful for the treatment of cancer, pain, dementia, Noonan syndrome, parkinsonism, neurofibromatosis type 1, atopic dermatitis and cholestasis, among others.
Characteristics of the tumor microenvironment are likely to contribute to the aggressiveness of triple-negative breast cancer (TNBC) and the extremely poor prognosis of those who suffer it. By analyzing patterns of gene expression in cancer-associated fibroblasts from TNBC tumors, researchers in China identified the PLAU gene as a driver of aggressive phenotype.
Immune checkpoint inhibitor therapy has proven effective against many types of solid tumors, but not many subtypes of ovarian cancer, including the rare subtype of ovarian clear cell carcinoma (OCCC). Now, researchers have identified a subtype of OCCC that involves inactivating mutations in the gene PPP2R1A and that responds well to immune checkpoint inhibitor therapy.
RSS
